At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 189 enrolled
Drug / intervention
SYM-1219 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
In Brief
A Phase 3 clinical trial evaluating SYM-1219 and Placebo for Bacterial Vaginosis. Completed, enrolled 189 participants across 21 sites.
Detailed Summary
The purpose of this clinical trial is to test the safety and efficacy of the oral investigational new drug, SYM-1219 for the treatment of bacterial vaginosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Vaginosis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionOct 2015
Study CompletionDec 2015
TodayJul 2026
First PostedApr 16, 2015
Enrollment StartMay 28, 2015
Primary CompletionOct 5, 2015
Study CompletionDec 5, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.2 years ago
Interventions
SYM-1219drug
Placebodrug